BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours

 BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours

BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Accelerated Approval for Patients with Mantle Cell Lymphoma Who Received At least One Prior Therapy

Shots:

  • The agreement involves assessing safety, efficacy and tolerability of BeiGene’s RAFi dimer, lifirafenib (BGB-283) and SpringWorks’ MEKi (PD-0325901), in patients with advanced solid tumours
  •  BeiGene will look forward for onset of P-Ib trial for advanced solid tumours while SpringWorks will oversee fixed dosing formulation in trial
  • The P-Ib trial is expected to initiate in Q1’19 while the costing and governance responsibilities of the trial will be shared equally b/w both the companies

Click here to read full press release/ article | Ref: BeiGene | Image:  Capital Watch

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post